High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Umino, Hiroyuki ^a   Hasegawa, Kazuhiro ^a   Minakuchi, Hitoshi ^a   Muraoka, Hirokazu ^a   Kawaguchi, Takahisa ^a   Kanda, Takeshi ^a   Tokuyama, Hirobumi ^a   Wakino, Shu ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; GLUCOSE; GLUCOSE TRANSPORTER 2; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; KARYOPHERIN ALPHA; SIRT1 PROTEIN, MOUSE; SIRTUIN 1; SLC2A2 PROTEIN, MOUSE; SLC5A2 PROTEIN, MOUSE; SMALL INTERFERING RNA; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL; C57BL MOUSE; CELL LINE; DIABETIC NEPHROPATHY; DIFFUSION CHAMBER; DRUG EFFECT; EPITHELIUM CELL; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY PROXIMAL TUBULE; KNOCKOUT MOUSE; MALE; METABOLISM; MOUSE; PATHOLOGY; PHARMACOLOGY; PIG; SIGNAL TRANSDUCTION;

ALPHA KARYOPHERINS; ANIMALS; CANAGLIFLOZIN; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DIFFUSION CHAMBERS, CULTURE; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TRANSPORTER TYPE 2; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; KIDNEY TUBULES, PROXIMAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIRTUIN 1; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SWINE;

EID: 85046343743     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-25054-y     Document Type: Article

References (58)

1. Roxburgh, S. A. et al. Allelic depletion of grem1 attenuates diabetic kidney disease. Diabetes. 58, 1641-1650 (2009).
2. Tervaert, T. W. C. et al. Pathologic classification of diabetic nephropathy. J. Am. Soc. Nephrol. 21, 556-563 (2010).
3. Bonventre, J. V. Can we target tubular damage to prevent renal function decline in diabetes? Semin. Nephrol. 32, 452-462 (2012).
4. Hasegawa, K. et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat. Med. 19, 1496-1504 (2013).
5. Wakino, S., Hasegawa, K. &Itoh, H. Sirtuin and metabolic kidney disease. Kidney Int. 88, 691-698 (2015).
6. Terami, N. et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 9, e100777 (2014).
7. Lu, Y., Griffen, S. C., Boulton, D. W. &Leil, T. A. Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans. Front. Pharmacol. 5, 274 (2014).
8. Hatanaka, T. et al. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect. 30, e00239 (2016).
9. Kitada, K. et al. Hyperglycemia causes cellular senescence via a SGLT2-and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy. J. Diabetes Complications. 28, 604-611 (2014).
10. Thrailkill, K. M. et al. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice. Bone. 82, 101-107 (2016).
11. Watanabe, Y. et al. Beneficial effect of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes. PLoS One. 10, e0116851 (2015).
12. Naznin, F. et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur. J. Pharmacol. 794, 37-44 (2017).
13. Shiba, K. et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci. Rep. 5, 2362 (2018).
14. Wen, D. et al. Resveratrol attenuates diabetic nephropathy via modulating angiogenesis. PLoS One. 8, e82336 (2013).
15. Kuriyama, C. et al. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats. J. Pharmacol. Exp. Ther. 351, 423-431 (2014).
16. Iijima, H., Kifuji, T., Maruyama, N. &Inagaki, N. Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv. Ther. 32, 768-782 (2015).
17. Penheiter, S. G. et al. Internalization-dependent and-independent requirements for transforming growth factor beta receptor signaling via the Smad pathway. Mol. Cell. Biol. 22, 4750-4759 (2002).
18. Kamiyama, M. et al. Detailed localization of augmented angiotensinogen mRNA and protein in proximal tubule segments of diabetic kidneys in rats and humans. Int. J. Biol. Sci. 10, 530-542 (2014).
19. Slattery, C., McMorrow, T. &Ryan, M. P. Overexpression of E2A proteins induces epithelial-mesenchymal transition in human renal proximal tubular epithelial cells suggesting a potential role in renal fibrosis. FEBS Lett. 580, 4021-4030 (2006).
20. Ohtomo, Y., Ono, S., Zettergren, E. &Sahlgren, B. Neuropeptide Y regulates rat renal tubular Na, K-ATPase through several signaling pathways. Acta Phsiol. Scand. 158, 97-105 (1996).
21. Panchapakesan, U. et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One. 8, e54442 (2013).
22. Takao, T. et al. Possible roles of tumor necrosis factor-α and angiotensin II type 1 receptor on high glucose-induced damage in renal proximal tubular cells. Ren. Fail. 37, 160-164 (2015).
23. Brown, R. D. et al. Reduced sensitivity of the renal vasculature to angiotensin II in young rats: the role of the angiotensin type 2 receptor. Pediatr. Res. 76, 448-452 (2014).
24. Tiedge, M. &Lenzen, S. Effects of glucose refeeding and glibenclamide treatment on glucokinase and GLUT2 gene expression in pancreatic B-cells and liver from rats. Biochem. J. 308, 139-144 (1995).
25. Diogo, L. N. et al. Voluntary oral administration of losartan in rats. J. Am. Assoc. Lab. Anim. Sci. 54, 549-556 (2015).
26. Liles, C. et al. AT2R autoantibodies block angiotensin II and AT1R autoantibody-induced vasoconstriction. Hypertension. 66, 830-835 (2015).
27. Zou, T. B. et al. The role of sodium-dependent glucose transporter 1 and glucose transporter 2 in the absorption of cyaniding-3-o-β-glucoside in Caco-2 cells. Nutrients. 6, 4165-4177 (2014).
28. Pontoglio, M. et al. HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 1, 359-365 (2000).
29. Guillemain, G. et al. Karyopherinalpha2: a control step of glucose-sensitive gene expression in hepatic cells. Biochem. J. 15, 201-209 (2002).
30. Pumroy, R. A. &Cingolani, G. Diversification of importin-α isoforms in cellular trafficking and disease states. Biochem. J. 466, 13-28 (2015).
31. Bjørkhaug, L., Bratland, A., Njølstad, P. R. &Molven, A. Functional dissection of the HNF-1alpha transcription factor: a study on nuclear localization and transcriptional activation. DNA Cell Biol. 24, 661-669 (2005).
32. Ye, W., Lin, W., Tartakoff, A. M. &Tao, T. Karyopherins in nuclear transport of homeodomain proteins during development. Biochim. Biophys. Acta. 1813, 1654-1662 (2011).
33. Blodgett, A. B. et al. A fluorescence method for measurement of glucose transport in kidney cells. Diabetes Technol. Ther. 13, 743-751 (2011).
34. Tucker, B. J., Rasch, R. &Blantz, R. C. Glomerular filtration and tubular reabsorption of albumin in preproteinuric and proteinuric diabetic rats. J. Clin. Invest. 92, 686-694 (1993).
35. Leturque, A., Brot-Laroche, E. &Le Gall, M. GLUT2 mutations, translocation, and receptor function in diet sugar managing. Am. J. Physiol. Endocrinol. Metab. 296, E985-E992 (2009).
36. Antoine, B. et al. Role of the GLUT 2 glucose transporter in the response of the L-type pyruvate kinase gene to glucose in liverderived cells. J. Biol. Chem. 272, 17937-17943 (1997).
37. Hughes, S. D., Johnson, J. H., Quaade, C. &Newgard, C. B. Engineering of glucose-stimulated insulin secretion and biosynthesis in non-islet cells. Proc. Natl. Acad. Sci. USA 89, 688-692 (1992).
38. Gouyon, F. et al. Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: a study in GLUT2-null mice. J. Physiol. 552, 823-832 (2003).
39. Guillam, M. T., Burcelin, R. &Thorens, B. Normal hepatic glucose production in the absence of GLUT2 reveals an alternative pathway for glucose release from hepatocytes. Proc. Natl. Acad. Sci. USA 95, 12317-12321 (1998).
40. Guillam, M. T. et al. Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat. Genet. 17, 327-330 (1997).
41. Cautain, B., Hill, R., de Pedro, N. &Link, W. Components and regulation of nuclear transport processes. FEBS J. 282, 445-462 (2015).
42. Cassany, A. et al. A karyopherin alpha2 nuclear transport pathway is regulated by glucose in hepatic and pancreatic cells. Traffic. 5, 10-19 (2004).
43. Köhler, M. et al. Increased importin alpha protein expression in diabetic nephropathy. Kidney Int. 60, 2263-2273 (2001).
44. Gu, N. et al. Glucose regulation of dipeptidyl peptidase IV gene expression is mediated by hepatocyte nuclear factor-1 alpha in epithelial intestinal cells. Clin. Exp. Pharmacol. Physiol. 35, 1433-1449 (2008).
45. Yamagata, K. Roles of HNF1α and HNF4α in pancreatic β-cells: lessons from a monogenic form of diabetes (MODY). Vitam. Horm. 95, 407-423 (2014).
46. Rodgers, J. T. et al. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 434, 113-118 (2005).
47. Zheng, Z. et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes. 61, 217-228 (2012).
48. Suchankova, G. et al. Concurrent regulation of AMP-activated protein kinase and SIRT1 in mammalian cells. Biochem. Biophys. Res. Commun. 378, 836-841 (2009).
49. Motta, M. C. et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 116, 551-563 (2004).
50. Santos, L., Escande, C. &Denicola, A. Potential modulation of Sirtuins by oxidative stress. Oxid. Med. Cell Longev. 2016, 9831825 (2016).
51. Hasegawa, K. et al. Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem. Biophys. Res. Commun. 372, 51-56 (2008).
52. Kume, S. et al. Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic. Biol. Med. 40, 2175-2182 (2006).
53. Jung, Y. J. et al. SIRT1 overexpression decreases cisplatin-induced acetylation of NF-kB p65 subunit and cytotoxicity in renal proximal tubule cells. Biochem. Biophys. Res. Commun. 419, 206-210 (2012).
54. Zhao, Y. et al. Sodium intake regulates glucose homeostasis through the PPARδ/adiponectin-mediated SGLT2 pathway. Cell Metab. 12(23(4)), 699-711 (2016).
55. Ji, W. et al. Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS One. 30(12(6)), e0179960 (2017).
56. Shiba, K. et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep. 5(8(1)), 2362 (2018).
57. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117-2128 (2015).
58. Bordone, L. &Guarente, L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat. Rev. Mol. Cell Biol. 6, 298-305 (2005).